244 related articles for article (PubMed ID: 21176111)
1. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro.
Aversa A; Caprio M; Antelmi A; Armani A; Brama M; Greco EA; Francomano D; Calanchini M; Spera G; Di Luigi L; Rosano GM; Lenzi A; Migliaccio S; Fabbri A
J Sex Med; 2011 Mar; 8(3):696-704. PubMed ID: 21176111
[TBL] [Abstract][Full Text] [Related]
2. The selectivity and potency of the new PDE5 inhibitor TPN729MA.
Wang Z; Zhu D; Yang X; Li J; Jiang X; Tian G; Terrett NK; Jin J; Wu H; He Q; Yang B; Shen J
J Sex Med; 2013 Nov; 10(11):2790-7. PubMed ID: 23937247
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model.
Aversa A; Fittipaldi S; Bimonte VM; Wannenes F; Papa V; Francomano D; Greco EA; Lenzi A; Migliaccio S
J Endocrinol Invest; 2016 Feb; 39(2):199-205. PubMed ID: 26134065
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
Limoncella S; Lazzaretti C; Paradiso E; D'Alessandro S; Barbagallo F; Pacifico S; Guerrini R; Tagliavini S; Trenti T; Santi D; Simoni M; Sola M; Di Rocco G; Casarini L
Mol Cell Endocrinol; 2022 Feb; 542():111527. PubMed ID: 34875337
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.
Morelli A; Sarchielli E; Comeglio P; Filippi S; Mancina R; Gacci M; Vignozzi L; Carini M; Vannelli GB; Maggi M
J Sex Med; 2011 Oct; 8(10):2746-60. PubMed ID: 21812935
[TBL] [Abstract][Full Text] [Related]
6. Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
Chhonker SK; Rawat D; Koiri RK
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23100. PubMed ID: 35608386
[TBL] [Abstract][Full Text] [Related]
7. Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Kruuse C; Gupta S; Nilsson E; Kruse L; Edvinsson L
Eur J Pharmacol; 2012 Jan; 674(2-3):345-51. PubMed ID: 22094063
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
Sanna F; Succu S; Boi A; Melis MR; Argiolas A
J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells.
Vernet D; Magee T; Qian A; Nolazco G; Rajfer J; Gonzalez-Cadavid N
J Sex Med; 2006 Jan; 3(1):84-94; discussion 94-5. PubMed ID: 16409221
[TBL] [Abstract][Full Text] [Related]
10. Transient rise of serum testosterone level after single sildenafil treatment of adult male rats.
Janjic MM; Stojkov NJ; Bjelic MM; Mihajlovic AI; Andric SA; Kostic TS
J Sex Med; 2012 Oct; 9(10):2534-43. PubMed ID: 22429315
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
12. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors.
Vignozzi L; Filippi S; Morelli A; Comeglio P; Cellai I; Sarchielli E; Maneschi E; Mancina R; Gacci M; Vannelli GB; Maggi M
J Sex Med; 2012 Dec; 9(12):3028-40. PubMed ID: 23057807
[TBL] [Abstract][Full Text] [Related]
13. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
[TBL] [Abstract][Full Text] [Related]
14. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome.
Filippi S; Vignozzi L; Morelli A; Chavalmane AK; Sarchielli E; Fibbi B; Saad F; Sandner P; Ruggiano P; Vannelli GB; Mannucci E; Maggi M
J Sex Med; 2009 Dec; 6(12):3274-88. PubMed ID: 19732305
[TBL] [Abstract][Full Text] [Related]
15. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
Corbin JD; Zoraghi R; Francis SH
Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
[TBL] [Abstract][Full Text] [Related]
16. The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.
Küçük A; Yucel M; Erkasap N; Tosun M; Koken T; Ozkurt M; Erkasap S
Mol Biol Rep; 2012 Oct; 39(10):9775-82. PubMed ID: 22736111
[TBL] [Abstract][Full Text] [Related]
17. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
18. Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects.
Foresta C; Caretta N; Zuccarello D; Poletti A; Biagioli A; Caretti L; Galan A
Eye (Lond); 2008 Jan; 22(1):144-9. PubMed ID: 17585311
[TBL] [Abstract][Full Text] [Related]
19. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
Shindel AW
J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
[TBL] [Abstract][Full Text] [Related]
20. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
